BTIG raised the firm’s price target on Syndax (SNDX) to $43 from $35 and keeps a Buy rating on the shares. The firm cites the company having announced FDA approval of REVUFORJ, revumenib, for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients, which comes 6-weeks earlier than the December 26 PDUFA date, the analyst tells investors in a research note. The label is fairly consistent with expectations on safety and efficacy, and BTIG does not see the recommendation for QTc monitoring initially with treatment as burdensome, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax price target raised to $51 from $49 at H.C. Wainwright
- Syndax confirms FDA approval of Revuforj for acute leukemia
- FDA approves Syndax’s Revuforj for acute leukemia
- Biotech Alert: Searches spiking for these stocks today
- Charter to acquire Liberty Broadband, Spotify reports Q3 beat: Morning Buzz